Histological reversibility of diabetic nephropathy after kidney transplantation from diabetic donor to non-diabetic recipient

Nephrology (Carlton). 2015 Jul:20 Suppl 2:40-4. doi: 10.1111/nep.12451.

Abstract

Aim: Given the recent increase in the prevalence of diabetes mellitus, it is not uncommon for kidney transplantation donors to have diabetes. We perform kidney transplantation in our hospital if the diabetic donors are receiving oral hypoglycaemic agents, but not insulin, and their haemoglobin A1C (HbA1C) is below 6.5%. There are few reports about histological changes to diabetic nephropathy after transplantation of kidney grafts from donors with diabetes mellitus to non-diabetic recipients. Therefore, we studied the histological diabetic changes in grafts from diabetic donors at protocol biopsies (1 hour, 1 month, 1 year), and evaluated whether they improved under the recipient's good glycaemic control.

Methods: Three cases of kidney transplantation from donors with diabetes mellitus to non-diabetic recipients were selected. We used a pathological classification established by the Renal Pathology Society for evaluating histological improvements in diabetic nephropathy.

Results: The results revealed that early diabetic changes found at the 1-hour and 1-month protocol biopsies were reversed and improved at the 1-year biopsy.

Conclusion: We concluded that early diabetic changes in grafts from diabetic donors may improve if the graft recipient has good glycaemic control after kidney transplantation.

Keywords: Diabetic nephropathy; donor; kidney transplantation; reversibility.

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Allografts
  • Biomarkers / blood
  • Biopsy
  • Child
  • Diabetic Nephropathies / blood
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / pathology*
  • Donor Selection*
  • Female
  • Glycated Hemoglobin / metabolism
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Kidney / pathology*
  • Kidney Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Remission Induction
  • Risk Factors
  • Time Factors
  • Tissue Donors*
  • Treatment Outcome

Substances

  • Biomarkers
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • hemoglobin A1c protein, human